Where does Novozymes A/S rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Novozymes A/S ranks #581 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Novozymes A/S hold?

Novozymes A/S holds 770 US utility patents granted between 2015 and 2025, spanning 73 technology areas.

What is Novozymes A/S's Innovation Score?

Novozymes A/S has an Innovation Score of 63.6 out of 100 (top 2% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Novozymes A/S's patent grant rate increasing or decreasing?

Novozymes A/S's recent grant velocity is -7% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Novozymes A/S's patents?

Novozymes A/S's patents average 18.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Novozymes A/S patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Novozymes A/S

Q: What technology areas does Novozymes A/S focus on?

Novozymes A/S's top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 656 patents. Grants appear in 73 CPC subclasses total.

USPTO PatentsView assignee record - 770 granted patents across 73 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Novozymes ranks #581 of 49,997 tracked US assignees by granted-patent volume, with 770 patents across 73 technology areas.

#581
of 49,997 US assignees by volume: Top 2%
by Innovation Score (63.6/100): 18.7
avg claims per patent: -7%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R581 · Foreign Corporation #581 · 770 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-STRONG · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL

GRANTS-MID 770 grants
TOP-DECILE #581/49,997
PHOTO-FINISH Axis AB
CPC-WIDE C12N · 73 areas
INNOV-STRONG 63.6/100
CLAIMS-RICH 18.7 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-FLAT -7% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Axis AB (±1 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Maxell · near

64
Hefei Institutes of… · near

64
MKS Instruments · near

64
Novozymes A/S · this assignee

64
Rolls-Royce · near

64
3D Lighting… · lowest

7

What this shows Novozymes's Innovation Score is 63.6/100 (top 2% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

How Novozymes's grant cadence moved

Between 2020–2024, Novozymes A/S received 350 grants versus 378 in 2015–2019 (-7% equal-window velocity, above median growth). Across complete PatentsView years, output peaked in 2020 at 98 grants and bottomed in 2015 at 48. Lead class C12N accounts for 85.2% of the portfolio across 73 subclasses. Volume neighbours: Mitsubishi Electric Research Laboratories, Inc. (#577) and Medtronic Minimed, Inc. (#585).

Novozymes's three-year grant acceleration

From 2019–2021 to 2022–2024, Novozymes A/S moved from 263 to 173 grants (0.66x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,282. See the growth leaderboard.

Mitsubishi Electr…

780
Chevron Phillips…

777
SK Telecom

772
Hitachi Construct…

771
Novozymes A/S ◀

770
Axis AB

769
Globalfoundries S…

769
Janssen Pharmaceu…

769
Medtronic Minimed

769

What this shows Novozymes holds 770 patents at rank #581, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Novozymes

By rank, the assignees closest to #581 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Novozymes's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Novozymes, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (64 here).

Rolls-Royce Corporation 64 MKS Instruments, Inc. 64 Hefei Institutes of Physical Sciences, Chinese Academy of Sciences 64 Maxell, Ltd. 64

Similar claim depth

Nearest assignees by average claims per patent (18.7 here).

Micro Focus LLC 18.7 avg FEI Company 18.7 avg Ramot at Tel-Aviv University Ltd. 18.7 avg AI Incorporated 18.7 avg

Novozymes's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

64 Top 2% higher than 98% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Novozymes A/S patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	48	6.2%
2016	79	10.3%
2017	85	11.0%
2018	80	10.4%
2019	86	11.2%
2020	98	12.7%
2021	79	10.3%
2022	66	8.6%
2023	49	6.4%
2024	58	7.5%
2025partial year	42	5.5%

Which technologies does Novozymes A/S patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 656

C12Y - Enzymes 540

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 348

C11D - Detergent COMPOSITIONS; USE OF Single Substances AS DETERGENTS; Soap OR SOAP-MAKING; Resin SOAPS; Recovery OF Glycerol 275

Y02E - Reduction OF Greenhouse GAS [GHG] Emissions, Related TO Energy Generation, Transmission OR Distribution 228

A23K - Fodder 85

C07K - Peptides 76

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 52

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 51

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 32

A23L - Foods, Foodstuffs OR Non-alcoholic Beverages, NOT Otherwise Provided FOR; Preparation OR Treatment Thereof 31

A21D - Treatment OF Flour OR Dough FOR Baking, e.g. BY Addition OF MATERIALS; BAKING; Bakery Products 29

C11B - Producing, e.g. BY Pressing RAW Materials OR BY Extraction From Waste Materials, Refining OR Preserving Fats, Fatty Substances, e.g. Lanolin, Fatty Oils OR WAXES; Essential OILS; Perfumes 25

C13K - Saccharides Obtained From Natural Sources OR BY Hydrolysis OF Naturally Occurring Disaccharides, Oligosaccharides OR Polysaccharides 22

C12R - Indexing Scheme Associated With Subclasses C12c - C12q, Relating TO Microorganisms 20

Top 15 of 73 technology areas

Where it ranks

Overall rank by patents

#581

of 49,997 tracked assignees

Innovation Score

63.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Novozymes A/S's patent record in context - here's where to go next.

Novozymes A/S's lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 85.2% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #581 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Novozymes A/S against Mitsubishi Electric Research Laboratories, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 63.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.